Tags

Type your tag names separated by a space and hit enter

The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays.
Growth Horm IGF Res. 2012 Apr; 22(2):53-8.GH

Abstract

BACKGROUND

The GH-2000 project developed a method for detecting GH misuse based on the measurement of insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). The objective of this study was to develop decision limits for the GH-2000 score to detect GH misuse in elite athletes using two currently available commercial assays for each analyte.

SUBJECTS

404 male (mean age 23.9 yrs, range 12-37 yrs) and 94 female elite athletes (mean age 24.5 yrs, range 18-34 yrs) participated. Blood samples were collected according to World Anti-Doping Agency (WADA) guidelines at various sporting events including 238 samples collected as part of the UK Anti-Doping Testing Programme. Laboratory analysis: IGF-I was measured by Siemens Immulite IGF-I assay and Immunotech A15729 IGF-I IRMA. P-III-NP was measured by RIA-gnost P-III-P and the UniQ™ PIIINP RIA.

STATISTICAL ANALYSIS

The GH-2000 score decision limits were developed through the analysis of the elite athlete samples.

RESULTS

For males and females separately, the distributions of GH-2000 scores were consistent with Normal distributions. Using a specificity of 99.99% new decision limits were determined which included an allowance for uncertainty associated with calculations based on a finite sample size. One outlier was identified with results incompatible with normal physiology and tested positive with the current isoform GH test.

CONCLUSIONS

We have developed decision limits using currently available commercial assays to measure IGF-I and P-III-NP in elite athletes. This should allow the introduction of a test for GH misuse based on the measurement of these GH sensitive biomarkers.

Authors+Show Affiliations

Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22305721

Citation

Erotokritou-Mulligan, Ioulietta, et al. "The Development of Decision Limits for the Implementation of the GH-2000 Detection Methodology Using Current Commercial Insulin-like Growth factor-I and Amino-terminal Pro-peptide of Type III Collagen Assays." Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, vol. 22, no. 2, 2012, pp. 53-8.
Erotokritou-Mulligan I, Guha N, Stow M, et al. The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Horm IGF Res. 2012;22(2):53-8.
Erotokritou-Mulligan, I., Guha, N., Stow, M., Bassett, E. E., Bartlett, C., Cowan, D. A., Sönksen, P. H., & Holt, R. I. (2012). The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society, 22(2), 53-8. https://doi.org/10.1016/j.ghir.2011.12.005
Erotokritou-Mulligan I, et al. The Development of Decision Limits for the Implementation of the GH-2000 Detection Methodology Using Current Commercial Insulin-like Growth factor-I and Amino-terminal Pro-peptide of Type III Collagen Assays. Growth Horm IGF Res. 2012;22(2):53-8. PubMed PMID: 22305721.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The development of decision limits for the implementation of the GH-2000 detection methodology using current commercial insulin-like growth factor-I and amino-terminal pro-peptide of type III collagen assays. AU - Erotokritou-Mulligan,Ioulietta, AU - Guha,Nishan, AU - Stow,Michael, AU - Bassett,E Eryl, AU - Bartlett,Christiaan, AU - Cowan,David A, AU - Sönksen,Peter H, AU - Holt,Richard I G, Y1 - 2012/02/10/ PY - 2011/12/12/received PY - 2011/12/20/accepted PY - 2012/2/7/entrez PY - 2012/2/7/pubmed PY - 2012/8/9/medline SP - 53 EP - 8 JF - Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society JO - Growth Horm IGF Res VL - 22 IS - 2 N2 - BACKGROUND: The GH-2000 project developed a method for detecting GH misuse based on the measurement of insulin-like growth factor-I (IGF-I) and the amino-terminal pro-peptide of type III collagen (P-III-NP). The objective of this study was to develop decision limits for the GH-2000 score to detect GH misuse in elite athletes using two currently available commercial assays for each analyte. SUBJECTS: 404 male (mean age 23.9 yrs, range 12-37 yrs) and 94 female elite athletes (mean age 24.5 yrs, range 18-34 yrs) participated. Blood samples were collected according to World Anti-Doping Agency (WADA) guidelines at various sporting events including 238 samples collected as part of the UK Anti-Doping Testing Programme. Laboratory analysis: IGF-I was measured by Siemens Immulite IGF-I assay and Immunotech A15729 IGF-I IRMA. P-III-NP was measured by RIA-gnost P-III-P and the UniQ™ PIIINP RIA. STATISTICAL ANALYSIS: The GH-2000 score decision limits were developed through the analysis of the elite athlete samples. RESULTS: For males and females separately, the distributions of GH-2000 scores were consistent with Normal distributions. Using a specificity of 99.99% new decision limits were determined which included an allowance for uncertainty associated with calculations based on a finite sample size. One outlier was identified with results incompatible with normal physiology and tested positive with the current isoform GH test. CONCLUSIONS: We have developed decision limits using currently available commercial assays to measure IGF-I and P-III-NP in elite athletes. This should allow the introduction of a test for GH misuse based on the measurement of these GH sensitive biomarkers. SN - 1532-2238 UR - https://www.unboundmedicine.com/medline/citation/22305721/The_development_of_decision_limits_for_the_implementation_of_the_GH_2000_detection_methodology_using_current_commercial_insulin_like_growth_factor_I_and_amino_terminal_pro_peptide_of_type_III_collagen_assays_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1096-6374(11)00124-9 DB - PRIME DP - Unbound Medicine ER -